share_log

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

極光大麻 | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/11/06 06:17

Moomoo AI 已提取核心訊息

Aurora Cannabis Inc. reported strong Q2 fiscal 2024 results with net revenue increasing 19% to $164.6 million compared to $137.9 million in Q2 2023. Medical cannabis revenue grew 28% to $108.5 million, while consumer revenue declined to $22.0 million. Gross profit before fair value adjustments improved to $69.3 million from $33.2 million year-over-year.The company achieved net income from continuing operations of $6.5 million, compared to a loss of $19.8 million in the prior year period. Cash and cash equivalents stood at $84.9 million as of September 30, 2024. The company maintained its strong market position in medical cannabis across key international markets including Europe and Australia.Operating expenses increased slightly to $88.2 million from $85.7 million last year. The company recorded an impairment charge of $11.6 million related to assets held for sale in Uruguay as it plans to exit operations there. Management remains focused on operational efficiency and maintaining adequate liquidity through cost reductions and access to its shelf prospectus.
Aurora Cannabis Inc. reported strong Q2 fiscal 2024 results with net revenue increasing 19% to $164.6 million compared to $137.9 million in Q2 2023. Medical cannabis revenue grew 28% to $108.5 million, while consumer revenue declined to $22.0 million. Gross profit before fair value adjustments improved to $69.3 million from $33.2 million year-over-year.The company achieved net income from continuing operations of $6.5 million, compared to a loss of $19.8 million in the prior year period. Cash and cash equivalents stood at $84.9 million as of September 30, 2024. The company maintained its strong market position in medical cannabis across key international markets including Europe and Australia.Operating expenses increased slightly to $88.2 million from $85.7 million last year. The company recorded an impairment charge of $11.6 million related to assets held for sale in Uruguay as it plans to exit operations there. Management remains focused on operational efficiency and maintaining adequate liquidity through cost reductions and access to its shelf prospectus.
Aurora 大麻股公司公佈了2024財年第二季度的強勁業績，淨營業收入比2023年第二季度的13790萬增加了19%，達到16460萬。醫療大麻收入增長28%，達到10850萬，而消費收入下降至2200萬。毛利潤在公允價值調整前從去年的3320萬改善至6930萬。該公司從持續運營中實現凈利潤650萬，而去年同期則虧損1980萬。截至2024年9月30日，現金及現金等價物爲8490萬。公司在包括歐洲和澳洲在內的主要國際市場中保持了強大的醫療大麻市場地位。營業費用略微上升至8820萬，去年爲8570萬。由於計劃退出烏拉圭的業務，公司記錄了1160萬的資產減值損失。管理層繼續專注於運營效率，通過減少成本和獲得其櫃台發行說明書來維持足夠的流動性。
Aurora 大麻股公司公佈了2024財年第二季度的強勁業績，淨營業收入比2023年第二季度的13790萬增加了19%，達到16460萬。醫療大麻收入增長28%，達到10850萬，而消費收入下降至2200萬。毛利潤在公允價值調整前從去年的3320萬改善至6930萬。該公司從持續運營中實現凈利潤650萬，而去年同期則虧損1980萬。截至2024年9月30日，現金及現金等價物爲8490萬。公司在包括歐洲和澳洲在內的主要國際市場中保持了強大的醫療大麻市場地位。營業費用略微上升至8820萬，去年爲8570萬。由於計劃退出烏拉圭的業務，公司記錄了1160萬的資產減值損失。管理層繼續專注於運營效率，通過減少成本和獲得其櫃台發行說明書來維持足夠的流動性。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Petros Pharmaceuticals
    PTPI
    -- 0.2930
    坎伯蘭藥業
    CPIX
    -- 5.150
    OptiNose
    OPTN
    -- 6.000
    Talphera
    TLPH
    -- 0.670
    BioAge Labs
    BIOA
    -- 4.790
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日